Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. (CLLS) news covers the activities of a clinical-stage biotechnology company focused on gene-edited cell and gene therapies. The company regularly issues updates on its allogeneic CAR-T pipeline, gene-editing technology advances, strategic collaborations, and financial position, providing a detailed view of how its programs evolve over time.
Investors and observers following Cellectis news can read about clinical data from key trials such as BALLI-01 for lasme-cel (UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia and NATHALI-01 for eti-cel (UCART20x22) in relapsed/refractory non-Hodgkin lymphoma. Press releases describe response rates, safety findings, and trial design features, as well as plans for pivotal Phase 2 development and data presentations at major scientific meetings.
Cellectis also publishes research and technology updates, including work on circular single-stranded DNA (CssDNA) as a non-viral donor template for gene insertion in hematopoietic stem and progenitor cells and studies of TALE base editors in primary T cells. These announcements highlight how the company applies its gene-editing platform beyond CAR-T therapies.
Additional news items address collaborations with partners such as AstraZeneca, Servier, Allogene, and Iovance, along with arbitration outcomes, financial results, cash runway disclosures, and monthly information on share capital and voting rights. By reviewing this news feed, readers can track both scientific progress and corporate developments that shape the outlook for Cellectis and its CLLS listing.
Cellectis (NASDAQ: CLLS) presented Phase 1 BALLI-01 data for lasme-cel (UCART22) on Oct 16, 2025, showing encouraging activity in heavily pretreated r/r B-ALL patients and a planned pivotal path. Key clinical highlights: Process 2 ORR 69% (P2 n=22), RP2D ORR 83% (n=12) and target Phase 2 population ORR 100% (n=9); CR/CRi 56% in the target population with ~80% MRD-negative responses; median OS 14.8 months in MRD-negative CR/CRi. Safety was described as generally tolerable (CRS 2.5%, ICANS 5%, 8 related SAEs).
Regulatory/commercial: pivotal Phase 2 initiated (first patient expected Q4 2025), BLA targeted 2028, and illustrative 2035 peak gross sales ~$700M (U.S., EU4, UK).
Cellectis (NASDAQ: CLLS) is hosting an R&D Day in New York City on October 16, 2025 to present pipeline progress for its allogeneic cell therapy program.
Leadership and key opinion leaders will present the complete Phase 1 dataset and outline the pivotal Phase 2 trial design and commercial opportunity for lasme-cel (UCART22) in relapsed/refractory B‑ALL. The event runs 08:30–10:30 a.m. ET, is in-person and live via webcast, and a replay will be posted on the company website.
Cellectis (Euronext Growth: CLLS) published its monthly information on share capital and voting rights as of 09/30/2025. The company reports a total number of shares of 100,325,229 and a total number of voting rights of 89,413,272. The disclosure follows Article 223-16 of the General Regulation of the French financial markets authority and lists investor and media contacts for further information.
Cellectis (NASDAQ: CLLS) will present data at the ESGCT Annual Congress in Sevilla on Oct 7-10, 2025 showing advances in non-viral gene therapy and TALE base editors.
Key highlights: a poster on Oct 8, 2025 reports that kilobase-long circular single-stranded DNA (CssDNA) enabled high gene insertion rates in viable HSPCs and greater engraftment and maintenance of edits in a murine model versus AAV-edited HSPCs. A second poster on Oct 9, 2025 reports a comprehensive nuclear off-target analysis for TALE base editors (TALEB) in primary T cells with no observed bias toward C-to-T off-targets near CTCF sites, supporting TALEB safety for therapeutic engineering.
Cellectis (CLLS) has released its monthly share capital and voting rights report as of August 31, 2025. The company reported a total of 100,325,229 shares in its capital structure and 89,428,230 voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority for companies listed on Euronext Growth.
Cellectis (CLLS) has reported its monthly share capital and voting rights information as of July 31, 2025. The company disclosed a total of 100,325,229 shares in its capital structure and 89,428,630 total voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority for its listing on Euronext Growth.
Cellectis (NASDAQ:CLLS) reported Q2 2025 financial results and significant pipeline developments. The company's cash position stands at $230 million, providing runway into H2 2027. Key developments include the completion of end-of-Phase 1 meetings with FDA & EMA for lasme-cel (UCART22) in r/r B-ALL, with pivotal Phase 2 launch planned for H2 2025.
Financial highlights show consolidated revenues of $30.2 million for H1 2025, up from $16.0 million in H1 2024, primarily driven by a $20.0 million increase in AstraZeneca collaboration revenue. The company reported a net loss of $41.9 million ($0.42 per share) compared to $19.6 million ($0.24 per share) in the same period last year.
Pipeline progress includes ongoing Phase 1 study of eti-cel (UCART20x22) in r/r NHL with readout expected in late 2025, and advancement of three programs under the AstraZeneca partnership. A Servier arbitration decision is expected by December 15, 2025.
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell therapies, will release its second quarter 2025 financial results on August 4, 2025 after U.S. market close.
The company will host an investor conference call and webcast on August 5, 2025 at 8:00 AM ET / 2:00 PM CET to discuss Q2 results and provide business updates. Investors can access the call through domestic (+1-800-343-5172) or international (+1-203-518-9856) dial-in numbers using Conference ID: CLLSQ2.
Cellectis (NASDAQ:CLLS) has released its monthly share capital and voting rights report as of June 30, 2025. The company reported a total of 100,325,229 shares in its capital structure and 89,428,630 voting rights.
This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority, as the company is listed on Euronext Growth.
Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company focused on gene-editing therapies, held its shareholders general meeting on June 26, 2025. With approximately 57% of voting rights exercised, shareholders approved 25 out of 26 resolutions.
The meeting resulted in significant board changes: Mr. André Muller, current CEO of Idorsia Pharmaceuticals, was appointed as a new board member, while Mr. Pierre Bastid resigned and Mr. Axel-Sven Malkomes' term expired. Muller brings extensive experience from his roles at Idorsia, Actelion Pharmaceuticals, and Pierre Fabre SA.
FAQ
What is the current stock price of Cellectis (CLLS)?
What is the market cap of Cellectis (CLLS)?
